Jaesung Heo1, O Kyu Noh2,3,4, Young-Taek Oh1, Mison Chun1, Logyoung Kim5. 1. Department of Radiation Oncology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon, 16499, Republic of Korea. 2. Department of Radiation Oncology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon, 16499, Republic of Korea. okyunoh@gmail.com. 3. Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea. okyunoh@gmail.com. 4. Office of Biostatistics, Ajou University School of Medicine, Suwon, Korea. okyunoh@gmail.com. 5. Health Insurance Review and Assessment Service, Seoul, Korea.
Abstract
PURPOSE: The aim of this study is to evaluate prevalence of second primary cancer (SPC) among hepatocellular carcinoma (HCC) patients after liver transplantation (LT) by using nationwide claims data from South Korea. MATERIALS AND METHODS: The nationwide cohort included patients who were diagnosed with HCC and received LT from 1 January 2010 to 31 December 2014. We analyzed frequency and standardized incidence ratios (SIRs) to estimate the risk of SPC in HCC patients after LT. RESULTS: A total of 2462 patients who were diagnosed with HCC and received LT were confirmed. Of these patients, 103 (4.2%) developed SPC after LT; the most common cancer site was lung (16.5%). Patients with HCC receiving LT had high risk of SPC [SIR 2.79, 95% confidence interval (CI) 2.27-3.38], particularly lymphoma (SIR 9.26), myeloma (SIR 10.60), and bladder cancer (SIR 7.19). The 12-, 24-, 36-, and 48-month overall survival for patients with HCC after LT was 92.7, 87.8, 84.6, and 82.1%, respectively. CONCLUSIONS: HCC patients with LT had longer life expectancy and higher risk for SPC compared with the general population. Therefore, close surveillance for SPC is important in patients with HCC receiving LT.
PURPOSE: The aim of this study is to evaluate prevalence of second primary cancer (SPC) among hepatocellular carcinoma (HCC) patients after liver transplantation (LT) by using nationwide claims data from South Korea. MATERIALS AND METHODS: The nationwide cohort included patients who were diagnosed with HCC and received LT from 1 January 2010 to 31 December 2014. We analyzed frequency and standardized incidence ratios (SIRs) to estimate the risk of SPC in HCC patients after LT. RESULTS: A total of 2462 patients who were diagnosed with HCC and received LT were confirmed. Of these patients, 103 (4.2%) developed SPC after LT; the most common cancer site was lung (16.5%). Patients with HCC receiving LT had high risk of SPC [SIR 2.79, 95% confidence interval (CI) 2.27-3.38], particularly lymphoma (SIR 9.26), myeloma (SIR 10.60), and bladder cancer (SIR 7.19). The 12-, 24-, 36-, and 48-month overall survival for patients with HCC after LT was 92.7, 87.8, 84.6, and 82.1%, respectively. CONCLUSIONS: HCC patients with LT had longer life expectancy and higher risk for SPC compared with the general population. Therefore, close surveillance for SPC is important in patients with HCC receiving LT.
Entities:
Keywords:
Hepatocellular carcinoma; Liver transplantation; Second primary cancer; South Korea
Authors: Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: M Shimada; K Takenaka; Y Fujiwara; T Gion; K Shirabe; T Nishizaki; K Yanaga; K Sugimachi Journal: Am J Gastroenterol Date: 1996-04 Impact factor: 10.864
Authors: Wen-Yi Huang; Deborah M Winn; Linda M Brown; Gloria Gridley; Eleuterio Bravo-Otero; Scott R Diehl; Joseph F Fraumeni; Richard B Hayes Journal: Am J Epidemiol Date: 2003-05-15 Impact factor: 4.897
Authors: M Qiu; Y Y Lian; M Lu; B S Wang; X J Tian; J Lu; C Liu; S D Zhang; M Jiang; L L Ma Journal: Beijing Da Xue Xue Bao Yi Xue Ban Date: 2022-08-18